Harmony Biosciences Q3 2022 net revenue $117.2M, up 45% YoY; GAAP EPS $1.44, non-GAAP EPS $0.95

Harmony Biosciences Holdings, Inc.

2022-Q3 EPS reported $2.18 revenue$309,547,000

Net product revenue $117.2M (+45% vs Q3 2021); average WAKIX patients ~4,600.
GAAP net income $87.9M ($1.44 diluted EPS) vs loss of $9.6M in prior year; includes $74.5M tax benefit.
Non-GAAP adjusted net income $58.1M ($0.95 diluted EPS) vs $23.4M ($0.41) in prior year.
PWS Phase 2 POC study positive signal on EDS; high-dose pitolisant higher responder rate vs placebo.
Cash, cash equivalents & investments $316M as of Sep 30, 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Harmony Biosciences Holdings, Inc. reported the quarter ended September 30, 2022 results: revenue $117.2 million, net income $87.9 million, EPS $1.44 per diluted share.

Period: the quarter ended September 30, 2022
Revenue: $117.2 million
Net income: $87.9 million
EPS: $1.44 per diluted share
Result: reported results

Exact text from the filing

reference. --- EX-99.1 (EX-99.1) --- ‌ Exhibit 99.1 HARMONY BIOSCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATES WAKIX® (pitolisant) Net Revenue of $117.2 Million for Third Quarter 2022 Increase of ~45% vs. the Same Period in 2021 Average Number of Patients on WAKIX Increased to ~4,600 Prader-Willi Syndrome (PWS) Phase 2

View on SEC.gov

Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-015722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.